Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
Last updated: 2026-11-17 03:23:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Gilead Sciences Inc. (GILD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $167.57, with a market capitalization of $208.48B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $116.88 to $176.58. This page covers its latest market performance, valuation, price trends and company information.
$208.48B | |
$171.04 | |
$171.72 | |
$166.92 | |
$168.08 | |
3.30M | |
6.02M | |
-- | |
$176.58 | |
$116.88 | |
1.97% | |
12-31 |
Gilead Sciences Inc. (GILD) last closed at $167.57 as of 2026-11-17 00:59:00, down 0.28% ($0.47) from the previous close of $168.08.
During the latest regular trading session, GILD traded between $166.92 and $171.72, with a volume of 3.30M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Gilead Sciences Inc. (GILD) moved from $167.57 to $167.57, representing a decline of 0.00% ($0.00).
The stock traded between $164.00 and $176.58 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 5.60 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.9%
GILD is currently trading at $167.57, placing it 84.9% of the way from its 52-week low of $116.88 to its 52-week high of $176.58. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17,000 |
| CEO | Daniel Patrick O'Day |
| Founded | 1987 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Gilead Sciences Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Dec 15, 2026 |
| Payment Date | Dec 30, 2026 |
| Dividend Per Share | $0.82 |
Latest news related to Gilead Sciences Inc. and GILD stock.
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
State Street's XPH (SPDR S&P Pharmaceuticals ETF) is recommended over Invesco's PBE (Biotechnology & Genome ETF) for long-term investors due to its lower expense ratio (0.35% vs 0.59%), broader diversification with 61 holdings, lower beta, and better recent 1-year performance (38.6% vs 33.2%). While PBE offers a higher dividend yield (1.3% vs 0.4%), XPH's exposure to pharmaceutical acquisitions and lower costs make it more suitable for most long-term investors.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Eligible investors can buy real shares of Gilead Sciences Inc. (GILD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GILD, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GILD shares and USD.
GILD Shares to USD
1.00 GILD shares = 167.569 USD
Calculations are estimates based on the latest available price and are for reference only.